Sanofi beats Q3 expectations, raises 2026 outlook and plans larger pipeline deals
Sanofi reported third-quarter net profit of 3.02 billion euros and core EPS of 3.55 euros, while net sales reached 14.44 billion euros, up 14% at constant foreign-exchange rates. Dupixent sales rose 35% at constant currency to 5.69 billion euros, helping offset a 6.6% decline in vaccine sales. Sanofi raised its 2026 targets to low-teens sales growth and mid-teens business EPS growth and said deals will help replenish its pipeline ahead of Dupixent's patent expiration.
Why it matters
The higher 2026 outlook increases Sanofi's near-term earnings expectations. Management says business development and M&A are needed to support the pipeline, while the company's concentration in Dupixent leaves investors focused on replacement products and future deal execution.
Key facts
- 1Sanofi's third-quarter net profit was 3.02 billion euros, compared with 2.81 billion euros a year earlier. morningstar.com
- 2Third-quarter net sales reached 14.44 billion euros, up 14% at constant foreign-exchange rates. morningstar.com
- 3Dupixent sales increased 35% at constant currency to 5.69 billion euros. morningstar.com
- 4Sanofi now expects full-year sales growth in the low-teens percentage range and business EPS growth in the mid-teens percentage range. morningstar.com
- 5Sanofi plans to pursue late-stage and commercial drug assets, with a focus on immunology, rare diseases and vaccines. biospace.com
Open questions
- Material 20 reports Dupixent growth of 40% year over year, while material 17 reports 35% at constant currency; the materials do not establish whether these figures use the same basis.
Summary written by AlphAI AI Desk from 20 of 20 sources. Not investment advice. Figures are as stated by the linked sources.